Company Profile
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung. The company also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of customer service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. It sells its products through direct sales organizations, such as capital and clinical sales teams. Intuitive Surgical, Inc. was incorporated in 1995 and is headquartered in Sunnyvale, California.
Latest News
ISRG vs. ABT: Which MedTech Giant Is the Smarter Investment Now?
Intuitive Surgical (ISRG) Unveils Five Layer AI Plan And Live Telesurgery Demo
Daiwa Securities Adjusts Price Target on Intuitive Surgical to $360 From $530, Maintains Outperform Rating
Zacks.com featured highlights include AIM ImmunoTech, Hasbro, Fox, Cencora and Intuitive Surgical
Review & Preview: An Earnings Week to Forget
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Website | https://www.intuitive.com |
| Audit Risk | 1 |
| Board Risk | 6 |
| Overall Risk | 4 |
| Market Cap | 120.92B |
| Trailing P/E | 38.75 |
| Forward P/E | 28.08 |
| Trailing Annual Div. Rate | 0 |
| Trailing Annual Div. Yield | 0.00% |
| Trailing EPS | 8.71 |
| Forward EPS | 12.02 |
| Book Value | 51.34 |
| Price-to-Book | 6.57 |
| Enterprise-to-Revenue | 10.34 |
| Enterprise-to-EBITDA | 27.3 |
| Short Ratio | 2.42 |
| Earnings Date | 10/20/2026 |
| Earnings Call Date | 07/16/2026 |
| Earnings Average | 2.63 |
| Earnings Low | 2.53 |
| Earnings High | 2.76 |
| Revenue Average | 2.90B |
| Revenue Low | 2.83B |
| Revenue High | 2.99B |